Qualification of Drivers; Exemption Applications; Implantable Cardioverter Defibrillators, 6463-6464 [2019-03384]
Download as PDF
amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 84, No. 39 / Wednesday, February 27, 2019 / Notices
analysis determined that only a 10,000foot runway was required to meet the
purpose and need. The analysis was
coordinated with the City of Charlotte
and its airline tenants. Given this
change to a major element of the
sponsor’s Proposed Action, the FAA
began a process of reevaluating the
appropriate level of environmental
documentation for compliance with
NEPA, the Council on Environmental
Quality Regulations for Implementing
the Procedural Provisions of NEPA (40
Code of Federal Regulations parts 1500–
1508), FAA Order 1050.1F,
Environmental Impacts: Policies and
Procedures, and FAA Order 5050.4B,
National Environmental Policy Act
(NEPA) Implementing Instructions for
Airport Actions. This evaluation
focused on likely changes to
environmental impacts anticipated to
occur as a result of the runway length
change.
In determining the appropriate level
of environmental review going forward,
the sponsor, at the request of the FAA,
has performed a preliminary noise
analysis of the revised Proposed Action.
In addition, the FAA has evaluated
potential changes in other anticipated
environmental impact categories. The
FAA has also considered potential
mitigation for such impacts. In light of
this review, the FAA anticipates that
compliance with NEPA can adequately
be achieved by preparation of an EA.
The City of Charlotte will be responsible
for the development of the EA in
accordance with NEPA, all applicable
federal regulations, and FAA guidance.
In addition, the FAA will work with the
City of Charlotte to ensure an
appropriate level of public involvement
is provided as part of the EA process.
Once completed, the City will forward
the environmental document to the
FAA. The FAA remains the responsible
Federal agency for compliance with the
requirements of NEPA. In this capacity,
FAA will make its own independent
evaluation of the environmental issues
and take responsibility for the scope and
content of the EA. The FAA also will
make a final decision on whether it can
issue a satisfactory environmental
finding based upon the EA. The FAA
will thereafter determine whether it may
take the federal actions necessary to
allow implementation of the project. All
questions concerning the development,
commencement, and public notices
related to the EA, should be directed to
The City of Charlotte Aviation
Department, Mr. Jack Christine, Chief
Operating Officer, 5601 Wilkinson
Boulevard, Charlotte, NC 28208.
More information on the Proposed
Action and the NEPA process is
VerDate Sep<11>2014
17:07 Feb 26, 2019
Jkt 247001
available on the project website at:
www.clteis.com.
Issued in Memphis, Tennessee on February
21, 2019.
Phillip J. Braden,
Manager, Memphis Airports District Office,
Southern Region.
[FR Doc. 2019–03434 Filed 2–26–19; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2018–0403]
Qualification of Drivers; Exemption
Applications; Implantable Cardioverter
Defibrillators
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of applications for
exemption; request for comments.
AGENCY:
FMCSA announces receipt of
applications from seven individuals for
an exemption from the prohibition in
the Federal Motor Carrier Safety
Regulations (FMCSRs) against operation
of a commercial motor vehicle (CMV) by
persons with a current clinical diagnosis
of myocardial infarction, angina
pectoris, coronary insufficiency,
thrombosis, or any other cardiovascular
disease of a variety known to be
accompanied by syncope, dyspnea,
collapse, or congestive heart failure. If
granted, the exemptions would enable
these individuals with implantable
cardioverter defibrillators (ICDs) to
operate CMVs in interstate commerce.
DATES: Comments must be received on
or before March 29, 2019.
ADDRESSES: You may submit comments
identified by the Federal Docket
Management System (FDMS) Docket ID
FMCSA–2018–0403 using any of the
following methods:
• Federal eRulemaking Portal: Go to
https://www.regulations.gov. Follow the
online instructions for submitting
comments.
• Mail: Docket Management Facility;
U.S. Department of Transportation, 1200
New Jersey Avenue SE, West Building
Ground Floor, Room W12–140,
Washington, DC 20590–0001.
• Hand Delivery: West Building
Ground Floor, Room W12–140, 1200
New Jersey Avenue SE, Washington,
DC, between 9 a.m. and 5 p.m., ET,
Monday through Friday, except Federal
Holidays.
• Fax: 1–202–493–2251.
To avoid duplication, please use only
one of these four methods. See the
SUMMARY:
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
6463
‘‘Public Participation’’ portion of the
section for
instructions on submitting comments.
FOR FURTHER INFORMATION CONTACT: Ms.
Christine A. Hydock, Chief, Medical
Programs Division, (202) 366–4001,
fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200
New Jersey Avenue SE, Room W64–224,
Washington, DC 20590–0001. Office
hours are from 8:30 a.m. to 5 p.m., ET,
Monday through Friday, except Federal
holidays. If you have questions
regarding viewing or submitting
material to the docket, contact Docket
Services, telephone (202) 366–9826.
SUPPLEMENTARY INFORMATION:
SUPPLEMENTARY INFORMATION
I. Public Participation
A. Submitting Comments
If you submit a comment, please
include the docket number for this
notice (Docket No. FMCSA–2018–0403),
indicate the specific section of this
document to which each comment
applies, and provide a reason for each
suggestion or recommendation. You
may submit your comments and
material online or by fax, mail, or hand
delivery, but please use only one of
these means. FMCSA recommends that
you include your name and a mailing
address, an email address, or a phone
number in the body of your document
so that FMCSA can contact you if there
are questions regarding your
submission.
To submit your comment online, go to
https://www.regulations.gov, put the
docket number, FMCSA–2018–0403, in
the keyword box, and click ‘‘Search.’’
When the new screen appears, click on
the ‘‘Comment Now!’’ button and type
your comment into the text box on the
following screen. Choose whether you
are submitting your comment as an
individual or on behalf of a third party
and then submit.
If you submit your comments by mail
or hand delivery, submit them in an
unbound format, no larger than 81⁄2 by
11 inches, suitable for copying and
electronic filing. If you submit
comments by mail and would like to
know that they reached the facility,
please enclose a stamped, self-addressed
postcard or envelope.
FMCSA will consider all comments
and material received during the
comment period.
B. Viewing Documents and Comments
To view comments, as well as any
documents mentioned in this notice as
being available in the docket, go to
https://www.regulations.gov. Insert the
docket number, FMCSA–2018–0319, in
the keyword box, and click ‘‘Search.’’
E:\FR\FM\27FEN1.SGM
27FEN1
amozie on DSK3GDR082PROD with NOTICES1
6464
Federal Register / Vol. 84, No. 39 / Wednesday, February 27, 2019 / Notices
Next, click the ‘‘Open Docket Folder’’
button and choose the document to
review. If you do not have access to the
internet, you may view the docket
online by visiting the Docket
Management Facility in Room W12–140
on the ground floor of the DOT West
Building, 1200 New Jersey Avenue SE,
Washington, DC 20590, between 9 a.m.
and 5 p.m., ET, Monday through Friday,
except Federal holidays.
to operate a CMV in interstate
commerce. [49 CFR part 391,
APPENDIX A TO PART 391—MEDICAL
ADVISORY CRITERIA, section D.
Cardiovascular: § 391.41(b)(4),
paragraph 4.] The advisory criteria
states that ICDs are disqualifying due to
risk of syncope.
C. Privacy Act
In accordance with 5 U.S.C. 553(c),
DOT solicits comments from the public
to better inform its rulemaking process.
DOT posts these comments, without
edit, including any personal information
the commenter provides, to
www.regulations.gov, as described in
the system of records notice (DOT/ALL–
14 FDMS), which can be reviewed at
www.dot.gov/privacy.
Mr. Caviola is commercial motor
vehicle driver who resides in New York
and operates in Connecticut. A June
2018, Physician’s Statement from his
cardiologist to the New York State
Department of Motor Vehicles states
that his ICD was implanted in 2005 and
during his ICD treatment has had no
therapies, history of syncope, or loss of
consciousness, with symptoms only
limited to palpitations.
II. Background
Under 49 U.S.C. 31136(e) and 31315,
FMCSA may grant an exemption from
the FMCSRs for a five-year period if it
finds such exemption would likely
achieve a level of safety that is
equivalent to, or greater than, the level
that would be achieved absent such
exemption. The statute also allows the
Agency to renew exemptions at the end
of the five-year period. FMCSA grants
exemptions from the FMCSRs for a twoyear period to align with the maximum
duration of a driver’s medical
certification.
The seven individuals listed in this
notice have requested an exemption
from 49 CFR 391.41(b)(4). Accordingly,
the Agency will evaluate the
qualifications of each applicant to
determine whether granting the
exemption will achieve the required
level of safety mandated by statute.
The physical qualification standard
found in 49 CFR 391.41(b)(4) states that
a person is physically qualified to drive
a CMV if that person has no current
clinical diagnosis of myocardial
infarction, angina pectoris, coronary
insufficiency, thrombosis, or any other
cardiovascular disease of a variety
known to be accompanied by syncope,
dyspnea, collapse, or congestive cardiac
failure.
In addition to the regulations, FMCSA
has published advisory criteria 1 to
assist Medical Examiners in
determining whether drivers with
certain medical conditions are qualified
John J. Groff
1 See https://www.ecfr.gov/cgi-bin/text-idx?
SID=e47b48a9ea42dd67d999246e23d97970&mc=
true&node=pt49.5.391&rgn=div5#ap49.5.391_171.a
and https://www.gpo.gov/fdsys/pkg/CFR-2015title49-vol5/pdf/CFR-2015-title49-vol5-part391appA.pdf.
VerDate Sep<11>2014
17:07 Feb 26, 2019
Jkt 247001
III. Qualifications of Applicants
Mark Caviola
Mr. Groff is a Class A CDL holder in
Pennsylvania. A November 2018, report
from his cardiologist states that his
CRT–D device was implanted in August
of 2018, and following placement he
showed likely improvement of his
ejection fraction to the 40–45 percent
range. His cardiologist reports that he
has never had required device therapies.
Kevin L. Krueger
Mr. Krueger is a commercial motor
vehicle driver in Nebraska. August and
December 2018 medical documentation
from his cardiologist reports that a dual
chamber ICD was implanted in 2009
and changed to a biventricular ICD in
January of 2018. His report indicated
ongoing monitoring of his device and
that he is tolerating medical therapy.
Michael R. Miller
Anthony Saitta
Mr. Saitta is a commercial motor
vehicle driver in New York. An undated
letter from his cardiologist reports that
his ICD was implanted in 2007 and that
since implantation the device deployed
once in 2016 inappropriately for atrial
tachycardia with rapid ventricular rate.
The letter states that Mr. Saitta reported
no symptoms other than feeling the
shock from the device, and that he did
Frm 00111
Fmt 4703
William Allan Spivey
Mr. Spivey is a Class A CDL holder
in North Carolina. A January 2019, letter
from his cardiologist reports that his
ICD was implanted in March of 2018.
His cardiologist reports that he has
never received shocks from his device,
at times has symptoms of shortness of
breath and occasional fatigue after
extended walking, and his current
cardiac condition is stable.
Aaron J. Thomas
Mr. Thomas is a commercial motor
vehicle driver in Georgia. A December
2018, letter from his cardiologist reports
that Mr. Thomas was implanted with an
ICD in November of 2018, and is
recovering well. He requires follow-up
every six months for proper monitoring
of his ICD and denies shortness of
breath or chest pain.
Request for Comments
In accordance with 49 U.S.C. 31136(e)
and 31315, FMCSA requests public
comment from all interested persons on
the exemption petitions described in
this notice. We will consider all
comments received before the close of
business on the closing date indicated
in the dates section of the notice.
Issued on: February 14, 2019.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2019–03384 Filed 2–26–19; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF THE TREASURY
Mr. Miller is a Class A CDL holder in
California. A January 2019 letter from
his cardiologist reports that his ICD was
implanted in September of 2018, and
that he has not received any type of
defibrillation since implantation, has
not had cardiovascular complaints and
is compliant with his current medical
regime.
PO 00000
not lose consciousness. Prior to and
since that event, the device has not
deployed and he has maintained a
stable cardiac status.
Sfmt 4703
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Form
5495—Request for Discharge From
Personal Liability Under Internal
Revenue Code Section 2204 or 6905
Departmental Offices, U.S.
Department of the Treasury.
ACTION: Notice.
AGENCY:
The Department of the
Treasury will submit the following
information collection requests to the
Office of Management and Budget
(OMB) for review and clearance in
accordance with the Paperwork
Reduction Act of 1995, on or after the
date of publication of this notice. The
public is invited to submit comments on
these requests.
SUMMARY:
E:\FR\FM\27FEN1.SGM
27FEN1
Agencies
[Federal Register Volume 84, Number 39 (Wednesday, February 27, 2019)]
[Notices]
[Pages 6463-6464]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-03384]
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2018-0403]
Qualification of Drivers; Exemption Applications; Implantable
Cardioverter Defibrillators
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.
ACTION: Notice of applications for exemption; request for comments.
-----------------------------------------------------------------------
SUMMARY: FMCSA announces receipt of applications from seven individuals
for an exemption from the prohibition in the Federal Motor Carrier
Safety Regulations (FMCSRs) against operation of a commercial motor
vehicle (CMV) by persons with a current clinical diagnosis of
myocardial infarction, angina pectoris, coronary insufficiency,
thrombosis, or any other cardiovascular disease of a variety known to
be accompanied by syncope, dyspnea, collapse, or congestive heart
failure. If granted, the exemptions would enable these individuals with
implantable cardioverter defibrillators (ICDs) to operate CMVs in
interstate commerce.
DATES: Comments must be received on or before March 29, 2019.
ADDRESSES: You may submit comments identified by the Federal Docket
Management System (FDMS) Docket ID FMCSA-2018-0403 using any of the
following methods:
Federal eRulemaking Portal: Go to https://www.regulations.gov. Follow the online instructions for submitting
comments.
Mail: Docket Management Facility; U.S. Department of
Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor,
Room W12-140, Washington, DC 20590-0001.
Hand Delivery: West Building Ground Floor, Room W12-140,
1200 New Jersey Avenue SE, Washington, DC, between 9 a.m. and 5 p.m.,
ET, Monday through Friday, except Federal Holidays.
Fax: 1-202-493-2251.
To avoid duplication, please use only one of these four methods.
See the ``Public Participation'' portion of the SUPPLEMENTARY
INFORMATION section for instructions on submitting comments.
FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division, (202) 366-4001, fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224,
Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m.,
ET, Monday through Friday, except Federal holidays. If you have
questions regarding viewing or submitting material to the docket,
contact Docket Services, telephone (202) 366-9826.
SUPPLEMENTARY INFORMATION:
I. Public Participation
A. Submitting Comments
If you submit a comment, please include the docket number for this
notice (Docket No. FMCSA-2018-0403), indicate the specific section of
this document to which each comment applies, and provide a reason for
each suggestion or recommendation. You may submit your comments and
material online or by fax, mail, or hand delivery, but please use only
one of these means. FMCSA recommends that you include your name and a
mailing address, an email address, or a phone number in the body of
your document so that FMCSA can contact you if there are questions
regarding your submission.
To submit your comment online, go to https://www.regulations.gov,
put the docket number, FMCSA-2018-0403, in the keyword box, and click
``Search.'' When the new screen appears, click on the ``Comment Now!''
button and type your comment into the text box on the following screen.
Choose whether you are submitting your comment as an individual or on
behalf of a third party and then submit.
If you submit your comments by mail or hand delivery, submit them
in an unbound format, no larger than 8\1/2\ by 11 inches, suitable for
copying and electronic filing. If you submit comments by mail and would
like to know that they reached the facility, please enclose a stamped,
self-addressed postcard or envelope.
FMCSA will consider all comments and material received during the
comment period.
B. Viewing Documents and Comments
To view comments, as well as any documents mentioned in this notice
as being available in the docket, go to https://www.regulations.gov.
Insert the docket number, FMCSA-2018-0319, in the keyword box, and
click ``Search.''
[[Page 6464]]
Next, click the ``Open Docket Folder'' button and choose the document
to review. If you do not have access to the internet, you may view the
docket online by visiting the Docket Management Facility in Room W12-
140 on the ground floor of the DOT West Building, 1200 New Jersey
Avenue SE, Washington, DC 20590, between 9 a.m. and 5 p.m., ET, Monday
through Friday, except Federal holidays.
C. Privacy Act
In accordance with 5 U.S.C. 553(c), DOT solicits comments from the
public to better inform its rulemaking process. DOT posts these
comments, without edit, including any personal information the
commenter provides, to www.regulations.gov, as described in the system
of records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.dot.gov/privacy.
II. Background
Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption
from the FMCSRs for a five-year period if it finds such exemption would
likely achieve a level of safety that is equivalent to, or greater
than, the level that would be achieved absent such exemption. The
statute also allows the Agency to renew exemptions at the end of the
five-year period. FMCSA grants exemptions from the FMCSRs for a two-
year period to align with the maximum duration of a driver's medical
certification.
The seven individuals listed in this notice have requested an
exemption from 49 CFR 391.41(b)(4). Accordingly, the Agency will
evaluate the qualifications of each applicant to determine whether
granting the exemption will achieve the required level of safety
mandated by statute.
The physical qualification standard found in 49 CFR 391.41(b)(4)
states that a person is physically qualified to drive a CMV if that
person has no current clinical diagnosis of myocardial infarction,
angina pectoris, coronary insufficiency, thrombosis, or any other
cardiovascular disease of a variety known to be accompanied by syncope,
dyspnea, collapse, or congestive cardiac failure.
In addition to the regulations, FMCSA has published advisory
criteria \1\ to assist Medical Examiners in determining whether drivers
with certain medical conditions are qualified to operate a CMV in
interstate commerce. [49 CFR part 391, APPENDIX A TO PART 391--MEDICAL
ADVISORY CRITERIA, section D. Cardiovascular: Sec. 391.41(b)(4),
paragraph 4.] The advisory criteria states that ICDs are disqualifying
due to risk of syncope.
---------------------------------------------------------------------------
\1\ See https://www.ecfr.gov/cgi-bin/text-idx?SID=e47b48a9ea42dd67d999246e23d97970&mc=true&node=pt49.5.391&rgn=div5#ap49.5.391_171.a and https://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/CFR-2015-title49-vol5-part391-appA.pdf.
---------------------------------------------------------------------------
III. Qualifications of Applicants
Mark Caviola
Mr. Caviola is commercial motor vehicle driver who resides in New
York and operates in Connecticut. A June 2018, Physician's Statement
from his cardiologist to the New York State Department of Motor
Vehicles states that his ICD was implanted in 2005 and during his ICD
treatment has had no therapies, history of syncope, or loss of
consciousness, with symptoms only limited to palpitations.
John J. Groff
Mr. Groff is a Class A CDL holder in Pennsylvania. A November 2018,
report from his cardiologist states that his CRT-D device was implanted
in August of 2018, and following placement he showed likely improvement
of his ejection fraction to the 40-45 percent range. His cardiologist
reports that he has never had required device therapies.
Kevin L. Krueger
Mr. Krueger is a commercial motor vehicle driver in Nebraska.
August and December 2018 medical documentation from his cardiologist
reports that a dual chamber ICD was implanted in 2009 and changed to a
biventricular ICD in January of 2018. His report indicated ongoing
monitoring of his device and that he is tolerating medical therapy.
Michael R. Miller
Mr. Miller is a Class A CDL holder in California. A January 2019
letter from his cardiologist reports that his ICD was implanted in
September of 2018, and that he has not received any type of
defibrillation since implantation, has not had cardiovascular
complaints and is compliant with his current medical regime.
Anthony Saitta
Mr. Saitta is a commercial motor vehicle driver in New York. An
undated letter from his cardiologist reports that his ICD was implanted
in 2007 and that since implantation the device deployed once in 2016
inappropriately for atrial tachycardia with rapid ventricular rate. The
letter states that Mr. Saitta reported no symptoms other than feeling
the shock from the device, and that he did not lose consciousness.
Prior to and since that event, the device has not deployed and he has
maintained a stable cardiac status.
William Allan Spivey
Mr. Spivey is a Class A CDL holder in North Carolina. A January
2019, letter from his cardiologist reports that his ICD was implanted
in March of 2018. His cardiologist reports that he has never received
shocks from his device, at times has symptoms of shortness of breath
and occasional fatigue after extended walking, and his current cardiac
condition is stable.
Aaron J. Thomas
Mr. Thomas is a commercial motor vehicle driver in Georgia. A
December 2018, letter from his cardiologist reports that Mr. Thomas was
implanted with an ICD in November of 2018, and is recovering well. He
requires follow-up every six months for proper monitoring of his ICD
and denies shortness of breath or chest pain.
Request for Comments
In accordance with 49 U.S.C. 31136(e) and 31315, FMCSA requests
public comment from all interested persons on the exemption petitions
described in this notice. We will consider all comments received before
the close of business on the closing date indicated in the dates
section of the notice.
Issued on: February 14, 2019.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2019-03384 Filed 2-26-19; 8:45 am]
BILLING CODE 4910-EX-P